Annual report pursuant to Section 13 and 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.8.0.1
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 01, 2015
Jul. 28, 2016
Jan. 26, 2016
Jun. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Termination of licensing agreement         $ 132,804
Agreement description         On March 31, 2016, the parties agreed to terminate the above described acquisition and to cancel any and all obligations assumed under the agreement.  
Intellectual property fees     $ 55,648      
Description for right to purchase perpetual rights     North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.      
Amortization expenses         $ 27,767 $ 25,918
Common shares outstanding         244,086,285 181,804,501
Therakine, Ltd. [Member]            
License cost   $ 2,750,000        
Aggregate purchase price   $ 250,000     $ 250,000 $ 250,000
Escrow deposit           75,000
Therakine, Ltd. [Member] | Minimum [Member]            
Milestone payments and royalties   5.00%        
Therakine, Ltd. [Member] | Maximum [Member]            
Milestone payments and royalties   12.00%        
Naltrexone Implant Formulation [Member]            
Estimated useful life       10 years    
Aggregate purchase price       $ 1,132,000   $ 1,132,000
Purchase obligation to pay       $ 1,000,000    
Acquired rights, title and interest payment period 14 months          
Common shares outstanding       3,000,000    
Market value       $ 0.044